Clinical-stage biotechnology company Cabaletta Bio promoted Heather Harte-Hall to the role of chief compliance officer.
Harte-Hall will continue to report to Gwendolyn Binder, the company’s executive vice president of science and technology. Harte-Hall joined Cabaletta in March 2019 and was most recently vice president of quality and compliance.
Previously, she was head of clinical quality and compliance at Adaptimmune Therapeutics, where she developed and implemented quality and compliance programs focusing on risk management and compliance functions to improve activities such as regulatory monitoring; auditing; and managing alignment with policies, procedures, and controls.
Harte-Hall has more than 15 years of experience in pharmaceutical and healthcare management and has held various positions in quality and compliance at Centocor Biotech, Wyeth, and Pfizer.